TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01783158

Intervention type: PROCEDURE
Intervention: Esophagoscopy and chromoendoscopy
Description: Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.~Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy.
Study: NCT00765154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darunavir
Description: two 400mg tablets (800mg) once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: one 100mg capsule once daily
Study: NCT00412880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 2536
Description: Intravenous Infusion
Study: NCT04266353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol (RSV)
Description: Participants will receive Resveratrol at 150 mg daily for 6 weeks.
Study: NCT02830542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-262
Description: SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
Study: NCT02239744

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Air purifiers
Description: The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air purifiers
Description: The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
Study: NCT03784781

Intervention type: BIOLOGICAL
Intervention: Biopsy
Description: Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe

Intervention type: BIOLOGICAL
Intervention: Biopsy
Description: Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: Blood collection (+15mL/ current care)

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: Blood collection (+15mL/ current care)

Intervention type: BIOLOGICAL
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage fluid (3mL/Kg)

Intervention type: BIOLOGICAL
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage fluid (3mL/Kg)
Study: NCT00541671

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10 c of saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenergan
Description: Physician ordered dose
Study: NCT02165397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive 420 mg of Ibrutinib orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive 420 mg of Ibrutinib orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo capsules orally.
Study: NCT01026337

Intervention type: PROCEDURE
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI

Intervention type: DRUG
Intervention: sunitinib malate
Description: Given orally

Intervention type: OTHER
Intervention: immunohistochemistry staining method
Description: Correlative study

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT02771925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 2g/day divided in two doses for 24 weeks
Description: Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.~All patients will receive standard of care treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2g/day divided in two doses for 24 weeks
Description: Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.
Study: NCT03528564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron sucrose
Description: Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Erythropoietin to be administered to half of study participants (40,000 IU x 1-2 subcutaneous injections)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
Study: NCT02470663

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DENSITYTM caplets (marketed as Amorphical)
Description: supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate 600 mg once daily
Description: supplementation
Study: NCT03268005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Only participants who took metformin before the study should take metformin tablets, same dose as before the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Study: NCT02165397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive rituximab 375 mg/m\^2 IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive rituximab 375 mg/m\^2 IV.
Study: NCT01855477

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Histological biopsy procedure
Study: NCT00210678

Intervention type: BEHAVIORAL
Intervention: No intervention
Description: No treatment is given to the patients as this is an observational study.

Intervention type: BEHAVIORAL
Intervention: No intervention
Description: No treatment is given to the patients as this is an observational study.
Study: NCT04059887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab Injection [Tecentriq]
Description: Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
Study: NCT04199455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules)
Description: Patients randomly assigned to the intervention group will receive EPACH and NQABC Chinese herbal compound granules, which will be manufactured by the Beijing Kangrentang Pharmaceutical company, combined with standard stroke care according to the Guidelines for the diagnosis and treatment of acute ischemic stroke in China 2018.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of EPACH recipe granules, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of NQABC recipe granules, dissolved with 200ml of boiled water, twice a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomly assigned to the intervention group will receive recipe simulators as placebo. EPACH and NQABC granules and recipe simulators are indistinguishable, identical in size, shape, color, appearance. Placebo is no decocting granules contain 5% original formula, 20% bitter gourd extract, 75% dextrin, and caramel color. Those who are assigned to the control group will be given placebo and guideline-based standard stroke treatment.~Route of administration: oral.~Dose regimen:~Day 1 to Day 5: in addition to the guideline-based standard treatment, 7.35g of recipe simulator, dissolved with 200ml of boiled water, twice a day.~Day 6 to Day 15: in addition to the guideline-based standard treatment, 6.85g of recipe simulator, dissolved with 200ml of boiled water, twice a day.
Study: NCT02226497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use home telemonitoring device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Receive standard outpatient supportive care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive standard outpatient supportive care
Study: NCT03962517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: with Gait Enhancing and Motivating System-Hip (GEMS-H)
Description: The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.~Assessments consist of gait function, cardiopulmonary metabolic energy cost, physical performance, balance, physical level, pain, fall efficacy, depression, quality of life and activities of daily living.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without Gait Enhancing and Motivating System-Hip (GEMS-H)
Description: The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.
Study: NCT03587519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early
Description: Early ileostomy closure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late
Description: Late ileostomy closure
Study: NCT03526978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational sIPV
Description: Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control IPV
Description: Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV
Study: NCT01184534

Intervention type: BEHAVIORAL
Intervention: Video
Description: 5 minute multimedia presentation (video)

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
Study: NCT04546022

Intervention type: DRUG
Group type: OTHER
Intervention: Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.
Study: NCT00236184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole sodium
Description: Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Study: NCT01085812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER
Description: Drug: Levomilnacipran ER (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to be given orally, in capsule form, once daily.
Study: NCT04150185

Intervention type: PROCEDURE
Intervention: Donor hepatectomy
Study: NCT00469456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine 20mg (10mg twice daily) oral administration for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo oral administration twice daily for 12 weeks
Study: NCT02541045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metadoxine
Description: metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets: 1 Tablet by mouth twice in day during 6 months
Study: NCT01035047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision unit care, coupled with cardiac MRI
Description: After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
Study: NCT02316288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Acceptance Therapy
Description: Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
Study: NCT02785731

Intervention type: PROCEDURE
Intervention: Pelvic imaging
Description: Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.

Intervention type: PROCEDURE
Intervention: laparotomy or laparoscopy
Description: A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
Study: NCT01168336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine standard formulation
Description: betahistine 24 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine Extended Release formulation
Description: betahistine 32 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT01973062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study: NCT00135577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvimopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT02720861

Intervention type: GENETIC
Intervention: DNA sequencing
Description: withdraw 3m blood from vein only once during the whole design to analyse on DNA sequencing on RNF213 rs112735431 Gene
Study: NCT00135577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05410119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-week Resilience Group Psychotherapy
Description: Resilience Group Psychotherapy was intervened by a psychotherapy developed by the researchers. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care means treating as usual, such as regular home visit.
Study: NCT01127321

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-570 0.03 MG
Description: A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-570 0.1 MG
Description: A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-570 0.3 MG
Description: A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-570 1 MG
Description: A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
Study: NCT00085111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT02171130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: 3 mg nasal glucagon powder
Study: NCT01895049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus
Study: NCT03202485

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toric Implantable Collamer Lens
Description: uses Toric Implantable Collamer Lens implantation to correct the high myopic astigmatism.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICL + Astigmatic keratotomy
Description: uses Implantable Collamer Lens implantation combined with Astigmatic keratotomy to correct the high myopic astigmatism
Study: NCT05098691

Intervention type: DIAGNOSTIC_TEST
Intervention: serum marker levels
Description: two groups comparisons

Intervention type: DIAGNOSTIC_TEST
Intervention: serum marker levels
Description: two groups comparisons
Study: NCT03535805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind My Mind (MMM)
Description: Mind My Mind (MMM) is a new transdiagnostic and modular cognitive and behavioural therapy (CBT) program comprising evidence-based interventions for children and adolescents with anxiety, depression or disruptive behavior.~MMM manual consists of evidence-based CBT methods that are organized into modules. The intervention is tailored to the individual child by the dosing and the sequencing of the modules. Trauma-focused CBT is available. Parents are engaged in child's therapy and support the child in doing the homework. Parent management training is offered for behavioral disturbances. The educational psychologists deliver the therapy after one-week training in the manual, followed by weekly supervision. The treatment fidelity is monitored by video observation of therapy sessions (\>20%).~The MMM training program consists of 9-13 sessions plus one booster, all completed within 17 weeks.